FDA Approves New Oral Option for Plaque Psoriasis - Poll - MDSpire

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

  • By

  • Kathryn Wighton

  • March 18, 2026

  • 2 min

Share

Original Source(s)

FDA Approves New Oral Option for Plaque Psoriasis

  • by Kathryn Wighton

  • March 18, 2026

Related Content

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse